A review of Dengvaxia®: development to deployment

SJ Thomas, IK Yoon - Human vaccines & immunotherapeutics, 2019 - Taylor & Francis
Dengue is the world's most prevalent and important arboviral disease. More than 50% of the
world's population lives at daily risk of infection and it is estimated more than 95 million …

[HTML][HTML] Dengue infection

MG Guzman, DJ Gubler, A Izquierdo… - Nature reviews Disease …, 2016 - nature.com
Dengue is widespread throughout the tropics and local spatial variation in dengue virus
transmission is strongly influenced by rainfall, temperature, urbanization and distribution of …

[HTML][HTML] Cross-reactive immunity among flaviviruses

APS Rathore, AL St. John - Frontiers in immunology, 2020 - frontiersin.org
Flaviviruses consist of significant human pathogens responsible for hundreds of millions of
infections each year. Their antigenic relationships generate immune responses that are …

Dengue viruses–an overview

A Tuiskunen Bäck, Å Lundkvist - Infection ecology & epidemiology, 2013 - Taylor & Francis
Dengue viruses (DENVs) cause the most common arthropod-borne viral disease in man
with 50–100 million infections per year. Because of the lack of a vaccine and antiviral drugs …

[HTML][HTML] Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine

R Shukla, V Ramasamy, RK Shanmugam… - Frontiers in cellular …, 2020 - frontiersin.org
In 2019, the United States Food and Drug Administration accorded restricted approval to
Sanofi Pasteur's Dengvaxia, a live attenuated vaccine (LAV) for dengue fever, a mosquito …

[HTML][HTML] Prospects for a dengue virus vaccine

SS Whitehead, JE Blaney, AP Durbin… - Nature Reviews …, 2007 - nature.com
The number of cases of severe dengue disease continues to grow in endemic areas of
southeast Asia, Central and South America, and other subtropical regions. Children bear the …

Dengue viral infections

GN Malavige, S Fernando, DJ Fernando… - Postgraduate …, 2004 - academic.oup.com
Dengue viral infections are one of the most important mosquito borne diseases in the world.
They may be asymptomatic or may give rise to undifferentiated fever, dengue fever, dengue …

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised …

JE Osorio, ID Velez, C Thomson, L Lopez… - The Lancet Infectious …, 2014 - thelancet.com
Background Dengue virus is the most serious mosquito-borne viral threat to public health
and no vaccines or antiviral therapies are approved for dengue fever. The tetravalent …

A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available

T Ishikawa, A Yamanaka, E Konishi - Vaccine, 2014 - Elsevier
Genus flavivirus comprises many important human pathogens causing public health
problems worldwide. Some flavivirus infections are characterized by a relatively high …

Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand

TP Endy, A Nisalak, S Chunsuttitwat… - The Journal of …, 2004 - academic.oup.com
Background. Infection with any 1 of the 4 dengue viruses (DVs) can produce several
illnesses, ranging from a mild febrile illness to classic dengue fever (DF) to dengue …